S&P 500 Financials Sector SEC Filings — March 20, 2026

20-03-2026

Cogent Communications Holdings, Inc.'s DEF 14A proxy statement details corporate governance practices, including full attendance by directors at the 2025 annual meeting and independence of all directors except CEO Dave Schaeffer. For 2025 executive compensation, base salaries for non-CEO Named Executive Officers increased 2.5%, CEO incentives achieved 152% of AWR CAGR target ($333,500 earned) but only 79% of GP CAGR target ($196,743), and sales commissions reached 92% for Mark Harris ($141,900) while at 77% for former CRO James Bubeck ($80,813). Significant long-term incentive grants were awarded, including up to 551,177 RSU shares for the CEO for 2026 service based on $12M notional value.

• ·All directors except CEO determined independent per Nasdaq rules.
• ·CEO 2025 LTIPs: 84,000 time-based RSUs and 96,000 performance-based RSUs (half EBITDA CAGR, half Free Cash Flow CAGR through 2027).
• ·CEO 2026 LTIPs: 229,657 time-based RSUs vesting 2029 and 321,520 performance-based RSUs based on EBITDA CAGR through 2028.
• ·Supplemental 100,000 time-based RSUs each to Chang, Harris, Weed vesting 2029 for Sprint acquisition retention.
• ·Performance-based RSUs for Weed, Chang, Kilmer based on customer satisfaction or performance through 2028.

20-03-2026

Avalon Holdings Corp's DEF 14A proxy statement discloses 2025 executive compensation, with CEO Ronald E. Klingle's total pay declining 5% YoY to $255,000 amid flat salary and lower bonus, while AWMS CEO Kenneth J. McMahon's total fell 10% to $480,669 on reduced performance-based bonus; CFO Michael J. Havalo's pay rose slightly 1% to $207,303. This aligns with weaker performance including net income dropping 76% YoY to $321,000 from $1.318M and shareholder return falling to $67 from $159. The filing seeks an advisory 'say-on-pay' vote and notes no equity awards, expired options, and no 401(k) contribution for 2025.

• ·Company is a controlled company with over 50% voting power held by Mr. Klingle; Compensation Committee not fully independent.
• ·No discretionary contribution to 401(k) Profit Sharing Plan for 2025.
• ·All prior stock options under Long-Term Incentive Plan expired; no outstanding equity awards at Dec 31, 2025.
• ·Non-employee directors received $24,000 in fees with no equity grants.
• ·AWMS Holdings LLC offers private placement to accredited investors for salt water facilities; consolidated due to control despite not majority owner.

20-03-2026

Wellgistics Health, Inc.'s 10-K filing describes its business operations across distribution, third-party logistics, and the DelivMeds digital pharmacy platform, supported by a network of over 5,000 pharmacies and facilities in Florida and Ohio. Acquisition-related consideration for Wellgistics LLC and Wood Sage includes $10M cash, $15M promissory note, and up to $25M in stock bonuses, with contingents tied to EBITDA targets through 2026. However, the filing emphasizes extensive risks including integration difficulties, reimbursement reductions, margin compression, and competitive pressures, with no financial performance metrics provided.

• ·Primary distribution center in Lakeland, Florida; additional facility in Columbus, Ohio; main office in Tampa, Florida.
• ·Contingent bonuses: 50% cash and 50% common stock if EBITDA exceeds 110% of targets for years ended Dec 31, 2024, 2025, and 2026.
• ·Promissory note interest: simple interest at Prime Rate as published by Wall Street Journal on Jan 1 of applicable year, payable in three equal annual installments starting first anniversary of registration effectiveness.
• ·Remainder of $10M cash due no later than earlier of 45 days post-registration effectiveness or Aug 30, 2025.

20-03-2026

20-03-2026

Claritev Corporation (CTEV) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials. No financial data, proposals, quantitative metrics, or period-over-period comparisons are included in the provided excerpt.

20-03-2026

Huntington Ingalls Industries, Inc. (HII) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on March 20, 2026. The filing constitutes soliciting material under §240.14a-12 for the registrant and requires no fee. No substantive financial or operational details are provided in the filing header.

20-03-2026

Aeva Technologies reported revenue of $18.1M for FY 2025, nearly doubling 99% YoY from $9.1M, with North America contributing 74% of revenue, while gross loss narrowed 83% to $0.7M. However, net loss improved only 4% to $145.4M from $152.3M amid a $21.5M negative change in warrant liability and high R&D expenses of $85.4M (down 17% YoY), leading to stockholders' equity dropping sharply to $13.2M from $99.4M due to $96.7M in new convertible notes. Cash and equivalents rose to $72.3M, supported by $128.6M in financing inflows.

• ·Revenue by geography FY2025: North America $13.3M (74%), Europe $3.9M (21%), Asia $0.6M (3%).
• ·Cash from financing FY2025: $128.6M primarily from $100M convertible notes and $32.5M private placement.
• ·Marketable securities declined to $49.6M from $83.1M as of Dec 31 2025.
• ·Weighted-average shares basic/diluted: 57.0M in FY2025 vs 53.4M in FY2024; net loss per share $(2.55) vs $(2.85).

20-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 20, 2026, announcing a press release stating that its RAD division has booked an order for 5 RIO 360 units destined for the Downtown Civic Center in a major Midwest city. This development underscores demand for AITX's AI-driven security solutions amid otherwise limited financial details in the filing.

• ·Filing includes Exhibit 99.1: Press release dated March 20, 2026

20-03-2026

Bio-Path Holdings, Inc. completed its domestication to Wyoming on March 5, 2026, and amended its articles of incorporation to authorize a new Series S Preferred Stock class with 51 shares, each convertible into one common share and holding 1% of diluted voting power. Effective February 10, 2026, Wendy M. Charles, PhD, MS, CIP, CCRP and Michael Hickey were appointed to the newly created Scientific Advisory Board, each signing a three-year agreement and receiving 100,000 stock options with a $0.06 exercise price and three-year term. No financial results or performance metrics were reported.

• ·Options have a three-year expiration and are subject to adjustment.
• ·Dr. Charles specializes in clinical research, regulatory compliance, oncology, and health IT.
• ·Mr. Hickey is VP Clinical Operations at Processa Pharmaceuticals with prior experience at Amgen and Biomarin.

20-03-2026

Papa Medical Inc., a provider of Hemp cannabinoid E-vapors and dosing solutions under the Cannapresso brand, filed Amendment No. 1 to its S-1 registration statement on March 19, 2026, for an IPO of 3,750,000 shares of Class A common stock at $4.00 per share, targeting $15M in gross proceeds before underwriting discounts. Net proceeds to the company are estimated at $13.95M, with an over-allotment option for 562,500 additional shares bringing totals to $17.25M gross and $16.04M net. The company, an emerging growth company and controlled entity (CEO Jian Hua holds 96.57% voting power post-offering), intends to list on Nasdaq under 'PAPA'.

• ·Company classified under SIC 2111 (Cigarettes), incorporated in Delaware with EIN 99-0986423.
• ·Principal offices at 202 North California Ave, City of Industry, CA 91744.
• ·Underwriters' over-allotment option exercisable for 45 days from prospectus date.
• ·Emerging growth company, smaller reporting company, and controlled company under Nasdaq rules.

20-03-2026

BigBear.ai Holdings, Inc. announced the reconvening of its Special Meeting of Stockholders on April 21, 2026, at 2:00 p.m. ET (originally convened December 1, 2025, and adjourned to March 18, 2026) to vote on Proposal 1: amending the Second Amended and Restated Certificate of Incorporation to increase authorized common shares from 500 million to 1 billion. The record date is March 30, 2026, with voting deadline April 20, 2026, 11:59 p.m. ET; previously submitted proxies will be voted unless revoked, and stockholders are urged to vote 'FOR' Proposal 1.

• ·Virtual meeting URL: www.virtualshareholdermeeting.com/BBAI2026
• ·Proxy voting options: Internet (www.proxyvote.com), Telephone (1-800-690-6903), Mail
• ·Proxy solicitor contact: (800) 662-5200 or BBAI@info.morrowsodali.com

20-03-2026

ACP Holdings Acquisition Corp., a blank check company focused on real estate & construction, filed an S-1/A registration statement (No. 333-294120) on March 20, 2026, for its initial public offering of units including Class A Ordinary Shares and warrants exercisable at $11.50. Union Street Sponsor, LLC acquired 7,666,667 Class B Ordinary Shares for $25,000 on January 29, 2026, with up to 1,000,000 subject to forfeiture to maintain 25% ownership post-IPO, and committed to purchase 390,000 Private Units. Proceeds from the IPO and Private Units will be deposited into a trust account with Odyssey Transfer & Trust Company.

• ·Company headquartered at 3131 Eastside, Houston, TX 77098.
• ·Standard Industrial Classification: Blank Checks [6770].
• ·Fiscal year end: December 31.
• ·EIN: 98-1923384.

20-03-2026

QIAGEN N.V. reported FY2025 net sales of $2.09B, up 6% YoY from $1.98B in FY2024, driven by 7% growth in consumables (90% of sales) and 10% increase in EMEA revenues. However, instrumentation sales declined 2% to $213.6M and Asia Pacific, Japan & Rest of World revenues fell 2% to $290.7M. Gross profit rose 34% to $1.30B with margin expansion to 62.2% from 48.9%, while product groups like Sample Technologies (+3%) and Other (+41%) showed varied performance.

• ·FY2023 total net sales were $1,965.3M.
• ·Instrumentation sales declined from $239.1M in FY2023 to $218.0M in FY2024 (-9%) and $213.6M in FY2025 (-2%).
• ·Employee functions stable: Sales 38% (up from 37%), Production 27% (down from 28%), R&D 17% (down from 18%) in FY2025.

20-03-2026

News Corporation filed an 8-K on March 20, 2026, disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1B stock repurchase program for Class A and Class B common stock, as required under ASX rules for daily transaction reporting. Exhibits 99.1 and 99.2 contain the specific details provided to the ASX on the respective dates noted therein. No specific repurchase transactions or amounts are detailed in the filing body.

• ·Filing relates to Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits).
• ·Securities: Class A Common Stock (NWSA), Class B Common Stock (NWS), both on Nasdaq Global Select Market.

20-03-2026

Belpointe PREP, LLC reported total assets of $564.2M as of Dec 31, 2025, up 9% YoY from $517.6M, driven by real estate net growth to $531.9M (+10% YoY), while revenue surged 244% YoY to $9.2M. However, net loss attributable to the company widened 68% YoY to $40.0M from $23.9M, with loss per Class A unit deteriorating to $(10.72) from $(6.56), amid higher debt ($260.6M, +47% YoY), elevated interest expense (+74% YoY), and negative NOI across Commercial (-$1.1M) and Mixed-use (-$1.3M) segments.

• ·Cash flows used in operating activities worsened to $(25.2M) in 2025 from $(13.7M) in 2024.
• ·Cash flows from financing activities declined to $87.0M in 2025 from $157.0M in 2024, leading to a net cash decrease of $0.2M.
• ·Commercial Segment NOI: $(1.1M) in 2025 vs $(0.05M) in 2024; Mixed-use Segment NOI: $(1.3M) in 2025 vs $(1.4M) in 2024 (slight improvement but still negative).

20-03-2026

Revenues and other income surged 61.7% YoY to $79.6M in 2025 from $49.2M in 2024, primarily driven by collaboration agreements rising to $72.1M (76.2% increase) and other revenues up 43.9% to $0.9M. However, net loss attributable to shareholders widened 83.9% to $67.6M from $36.8M, operating expenses increased with R&D up 3.3% to $93.5M and SG&A up 3.7% to $19.8M, cash and cash equivalents fell 19.8% to $208.7M, and shareholders' equity declined 42.1% to $75.9M.

• ·EPS basic and diluted FY2025: ($0.67), worsened from ($0.41) in FY2024.
• ·Total assets declined 15.4% to $324.7M as of Dec 31, 2025 from $383.5M.
• ·Adjusted Net Loss attributable to shareholders FY2025: $61.5M, vs $33.6M in FY2024.

20-03-2026

Embecta Corp. (Nasdaq: EMBC) announced a definitive agreement to acquire Owen Mumford Holdings Limited for up to £150 million (£100 million upfront cash plus up to £50 million in performance-based payments tied to Aidaptus® sales over three years post-closing). Owen Mumford generated £69.4 million in net revenue for its FY2025 (ended September 30), with approximately 80% from the UK and U.S., positioning the deal to expand Embecta's drug delivery portfolio and global reach. While expected to drive revenue growth and be accretive to adjusted net income after FY2028 with high-single-digit ROIC by year four, the acquisition will be dilutive to adjusted net income in FY2027.

• ·Expected closing in Embecta's fiscal Q3 2026, subject to regulatory approvals.
• ·Owen Mumford FY ends September 30.
• ·Financed by borrowings under Embecta's revolving credit facility.
• ·To be discussed on FY2026 Q2 earnings call on May 5, 2026.
• ·Owen Mumford founded in 1952, family-owned, headquartered in Oxfordshire, UK.

20-03-2026

Pelican Acquisition Corporation held an extraordinary general meeting on March 19, 2026, where shareholders overwhelmingly approved all six proposals related to the business combination with Greenland Energy Company, including the Business Combination, Conversion, and Governing Documents Proposals. However, in connection with the meeting, holders redeemed 7,562,343 ordinary shares (63% of outstanding shares) for $77.7M at $10.28 per share, significantly reducing trust account funds. The merger is expected to close on or around March 24, 2026, with Greenland's stock trading under 'GLND' on Nasdaq starting March 25, 2026.

• ·Record date: February 19, 2026
• ·Merger Agreement dated: September 9, 2025
• ·Proposal 1 (Business Combination): For 6,509,645; Against 400,135; Abstain 125,098
• ·Proposal 2 (Conversion): For 6,507,603; Against 402,162; Abstain 125,113
• ·Proposal 3 (Governing Documents): For 6,509,645; Against 400,135; Abstain 125,098
• ·Proposal 4 (Governing Documents Advisory): For 6,508,445; Against 401,335; Abstain 125,098
• ·Proposal 5 (Stock Issuance): For 6,506,635; Against 403,145; Abstain 125,098
• ·Proposal 6 (Incentive Plan): For 6,505,085; Against 403,345; Abstain 126,448

20-03-2026

Primoris Services Corporation (NYSE: PRIM) has issued its 2026 Proxy Statement for the virtual Annual Meeting of Stockholders on April 30, 2026, at 9:00 a.m. CT, where shareholders will vote on electing eight directors, advisory approval of named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditors for the fiscal year ending December 31, 2026. The company describes 2025 as an exceptional year, achieving record milestones, accelerating strategic growth, generating strong cash flow, and strengthening its balance sheet. Chairman David L. King thanks retiring Board member John Schauerman for his long service.

• ·Record date for shareholders entitled to vote: March 9, 2026
• ·Virtual meeting registration deadline: April 24, 2026, 11:59 p.m. Central Time at www.proxydocs.com/PRIM
• ·Principal executive offices: 2300 N. Field Street, Suite 1900, Dallas, Texas 75201

20-03-2026

Yellowstone MidCo Holdings II, LLC reported revenue growth of 52% YoY to $386M for 2025 from $254M in 2024, with gross profit tripling to $75M (20% margin from 13%) and Adjusted EBITDA improving to -$8M from -$43M. However, the company posted a net loss of $85M (narrowed 15% YoY), operating expenses increased 17% driven by higher SG&A (+11%) and transaction costs, R&D declined 10%, and net cash used in operations was $121M versus provided by $32M prior year.

• ·Net EAC adjustments before taxes: -$11.1M in 2025 vs -$22.9M in 2024.
• ·Minimum revenue guarantees extend to Sep 2028 at $758M.
• ·Cash increased $58M to $163M end-2025, driven by $204M financing inflows.

20-03-2026

StimCell Energetics Inc. (OTCQB: STME) engaged Stonegate Capital Partners, Inc. for research coverage and institutional investor outreach under an Advisory Services Agreement effective March 12, 2026, with services including quarterly research updates and coordination of investor meetings for a 12-month term. Compensation consists of 250,000 shares of common stock issued to Stonegate. CEO David Jeffs highlighted the partnership's potential to elevate visibility and build institutional ownership for the company's eBalance® technology.

• ·Shares subject to a six-month hold period from issuance date.
• ·Shares issued pursuant to exemptions from prospectus requirements of Canadian securities laws and registration requirements of U.S. Securities Act of 1933.
• ·Company focuses on products enhancing cellular function for wellness, anti-aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function.

20-03-2026

Cingulate Inc. filed an S-3 registration statement on March 20, 2026, to register up to 3,500,000 shares of common stock (part of a total 6M including prior registration) for resale by Lincoln Park under a July 21, 2025 Purchase Agreement committing up to $25M in common stock purchases over 36 months. The company issued 120,424 commitment shares to Lincoln Park without cash consideration. While this facility offers flexible capital access subject to market conditions and a $0.50 minimum price, it poses substantial dilution risks to existing shareholders, potential stock price declines, and limitations on full utilization due to ownership caps.

• ·Purchase Agreement entered July 21, 2025; 36-month term commencing after conditions met.
• ·Prior S-1 registration filed July 25, 2025 (effective July 29, 2025) for 2,500,000 shares.
• ·Regular Purchases allowed only if last closing sale price >= $0.50.
• ·Agreement terminable by company with one business day's notice without penalty.

20-03-2026

Firefly Aerospace reported revenue of $159.9M for 2025, up 163% YoY from $60.8M, driven by strong growth in Spacecraft Solutions (+244% to $131.2M) and Launch revenue (+26% to $28.6M); gross profit swung to $30.7M from a $11.4M loss. However, net loss widened 29% YoY to $298.3M, operating loss increased 24% to $260.7M amid 47% higher operating expenses, and cash used in operations rose 30% to $204.9M, though bolstered by $1.3B in financing inflows.

• ·Adjusted EBITDA was -$198.6M in 2025, worsening from -$190.6M in 2024.
• ·Free cash flow was -$237.8M in 2025, down from -$190.3M in 2024.
• ·Total assets grew to $1.8B from $407.3M; cash equivalents rose to $793M from $123.4M.
• ·Intangible assets $165.7M and goodwill $450.1M as of Dec 31 2025, primarily from acquisitions.
• ·Net loss per common share improved to -$4.83 from -$20.74, with weighted-average shares 69,204 vs 12,819.

20-03-2026

Prestige Consumer Healthcare Inc. announced an agreement to acquire the Breathe Right portfolio, including the #1 nasal strip brand, from Foundation Consumer Healthcare for $1.045B in cash (~$900M net of anticipated tax benefits), adding ~$200M LTM revenue (ended Dec 31, 2025) and ~$95M EBITDA at 11.0x multiple (9.5x net). The deal is immediately accretive to revenue, margins, EPS, and FCF, boosting pro-forma revenue to ~$1.3B from standalone ~$1.1B, financed by cash and new term loan with pro-forma net leverage ~4.0x at close (expected H1 FY27) and path to <3.0x by FY28. Historically, FY20-FY25 CAGRs show revenue +3.4%, organic revenue +2.4%, and adjusted EPS +8.8%, reflecting steady but modest organic growth.

• ·Target portfolio: 71% US & Canada revenue, 29% international (mostly Europe).
• ·Breathe Right provides ~30% immediate nasal airflow increase; loyal users average 150+ strips/year.
• ·Acquisition expected to close H1 FY27 (by Sep 30, 2026), subject to regulatory approvals.
• ·Historical net leverage: 4.1x Q2 FY22, down to 2.4x FY25 and FY26E.
• ·Prestige FY25 adjusted net income $226.3M (GAAP $214.6M); FY20 adjusted $151.3M (GAAP $142.3M).

20-03-2026

Civista Bancshares, Inc. issued a press release on March 19, 2026, announcing plans to release its first quarter 2026 financial results prior to market open on April 22, 2026. The company is a $4.4B financial holding company headquartered in Sandusky, Ohio, with primary subsidiary Civista Bank operating 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884
• ·Civista Leasing and Finance Division headquartered in Pittsburgh, Pennsylvania
• ·Common shares traded on NASDAQ under symbol CIVB
• ·Website: www.civb.com

20-03-2026

Dollar General's FY2025 net sales rose 5.2% YoY to $42.7B from $40.6B in FY2024, driven by 6.7% growth in home products and 6.2% in seasonal, while consumables grew 5.0% and apparel a modest 3.3%; average sales per square foot increased to $270 from $263. Operating profit surged 28.6% to $2.2B with gross margin expanding 107 bps to 30.66%, and net income climbed 34.4% to $1.5B. However, profitability metrics remained below FY2023 levels, with operating profit down 29.9% from $2.4B and net margin at 3.54% versus 4.29%.

• ·Average sales per square foot: $270 in FY2025 (up from $263 in FY2024)
• ·FY2025 SG&A expenses: $10.9B (5.8% YoY increase)
• ·FY2025 diluted EPS: $6.85 (34.1% YoY increase from $5.11)
• ·Self-insurance liabilities: $377.6M total

20-03-2026

The Board is actively overseeing AI integration, including appointing a Chief Artificial Intelligence Officer, establishing governance frameworks, and participating in executive education programs. As of December 31, 2025, employee headcount grew 10.2% YoY by 33 to 328 (326 full-time, 2 part-time), driven by business expansion and risk management strengthening, while gender diversity remained flat at 45% women and 55% men. The Board held 14 meetings in 2025 with an average attendance of 95%, and all directors attended the 2025 annual stockholder meeting.

• ·No employees represented by collective bargaining agreement.
• ·Board has four standing committees: Audit, Risk, CG&N, and Compensation (implied).
• ·Audit Committee oversees independent auditors, financial statements, and internal audit function.

20-03-2026

The Toro Company amended its Restated Certificate of Incorporation, authorizing a total of 176.85M shares of capital stock: 175M common shares (par value $0.01), 1M voting preferred shares (par value $0.01), and 850K non-voting preferred shares (par value $0.01). The amendment also updated Article X to refine provisions eliminating personal liability for directors and officers for breaches of fiduciary duty, with specific exceptions including for officers under Delaware law. These changes were duly adopted by the Board of Directors and stockholders.

• ·Original Certificate of Incorporation filed November 7, 1983
• ·Amendment executed March 17, 2026
• ·Adopted per Section 242 of Delaware General Corporation Law

20-03-2026

On March 13, 2026, Bowman Consulting Group Ltd. (BWMN) entered into a $146.7M contract amendment with a US government agency, increasing the total contract value to $177.7M from the original contract signed in December 2025. Bowman's services under this contract are expected to span 36 months. This represents a significant new revenue opportunity for the emerging growth company.

• ·Original contract entered into in December 2025.
• ·Registrant is an emerging growth company.
• ·Principal executive offices: 12355 Sunrise Valley Drive, Suite 520, Reston, Virginia 20191.

20-03-2026

Olin Corporation filed its DEF 14A definitive proxy statement on March 20, 2026, for the annual shareholder meeting with a conformed period end of April 30, 2026, detailing voting procedures, deadlines, and access to the 2025 Form 10-K. The Olin Retirement Savings Plan held 1,267,968 shares of common stock as of March 2, 2026, with voting instructions due by April 27, 2026, for RSP participants and April 29, 2026, for others. The filing includes references to executive compensation disclosures for Kenneth T. Lane and Scott M. Sutton covering 2021-2025 but provides no specific financial metrics or performance changes.

• ·Annual meeting voting deadline for non-RSP shareholders: April 29, 2026 by 11:59 p.m. Eastern Time
• ·RSP voting instructions deadline: April 27, 2026 by 11:59 p.m. Eastern Time
• ·Shareholder proposals for 2027 annual meeting (exclusion notice): no earlier than December 2, 2026 and no later than January 1, 2027
• ·Shareholder proposals for inclusion in 2027 proxy: no later than November 21, 2026
• ·Director nomination recommendations for 2027: no later than October 22, 2026
• ·No person beneficially owned more than 5% of common stock as of March 2, 2026, except as listed (table incomplete in filing excerpt)

20-03-2026

Milestone Pharmaceuticals reported first-year revenue of $1.5M for the year ended December 31, 2025, up 100% from $0 in 2024 following the US launch of CARDAMYST nasal spray, supported by a sales team of approximately 60 representatives targeting cardiology and primary care providers for an estimated 500,000 PSVT patients in 2026. However, total operating expenses rose 51.3% to $63.7M, driven by a 157.2% surge in commercial expenses to $28.3M and 26.1% increase in R&D to $18.1M, resulting in a widened net loss of $63.1M (51.9% worse than $41.5M in 2024). The company anticipates continued substantial operating losses until CARDAMYST revenue suffices.

• ·Company has incurred significant operating losses since inception and anticipates continued losses until CARDAMYST revenue is sufficient.
• ·Pursuing clinical development for subsequent etripamil indications beyond PSVT.

20-03-2026

Latham Group, Inc. (SWIM) filed a DEFA14A Definitive Additional Proxy Materials on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing was made by the registrant with no fee required. No substantive financial data, metrics, or period-over-period comparisons are disclosed in the provided filing header.

20-03-2026

Ermenegildo Zegna N.V. reported FY2025 revenues of €1,917M, down 1.5% YoY from €1,947M in FY2024 (which grew 2.2% from FY2023), with organic growth of 1.1%; while ZEGNA brand rose 1.5%, DTC sales increased 4.2%, and Americas grew 7.9%, Thom Browne declined 14.7%, wholesale branded fell 20.9%, and Greater China dropped 14.6%. Profit improved 20.5% to €109M from €91M, supported by gross margin expansion to 67.5% from 66.6%, though adjusted EBIT fell to €163M from €184M and operating profit margin contracted to 7.3% from 8.6%.

• ·Euro revenues declined to 27.9% of total (from 29.3%), while U.S. Dollar rose to 25.6% (from 23.7%) and Chinese Renminbi fell to 18.4% (from 20.8%).
• ·SG&A expenses increased to 53.9% of revenues from 51.8%, contributing to operating profit decline.
• ·DTC as % of branded products improved to 82.0% from 77.6%, while wholesale share fell to 18.0% from 22.4%.

20-03-2026

Victoria's Secret & Co. reported fiscal 2025 net sales of $6,553M, up 5% YoY from $6,230M, driven by 27% growth in International sales and 3% in North America stores, while Direct sales remained flat at $2,042M. Adjusted operating income increased 8% to $403M and adjusted net income rose 15% to $250M with EPS at $3.00 (up from $2.69); however, GAAP reported operating income declined 13% to $271M from $310M and net income edged down 2% to $161M due to a $120M Adore Me long-lived assets impairment and other restructuring charges. Productivity improved with sales per average selling square foot up 6% to $624 and per store up 7% to $4.3M, though total selling square feet fell 2%.

• ·Capital expenditures fiscal 2025: $187M (up from $178M)
• ·Long-term debt stable at $971M as of Jan 31, 2026 (vs $973M prior year)
• ·Amounts available under ABL Facility: $589M (up from $533M)
• ·Total selling square feet: 5,315 thousand (down 2% YoY)
• ·Future lease obligations total $2,452M, with $416M due within 1 year
• ·Purchase obligations: $877M, mostly due within 1 year ($817M)

20-03-2026

The E.W. Scripps Company (SSP) filed its DEF 14A Proxy Statement on March 20, 2026, for the 2026 Annual Meeting of Shareholders on May 4, 2026, at 4:00 PM ET in Cincinnati, OH, with record date March 10, 2026. Key proposals include election of directors, ratification of Deloitte & Touche LLP as independent auditors for 2026, advisory vote on 2025 named executive officer compensation, and ratification of the Shareholder Rights Plan adopted November 25, 2025, with the Board recommending FOR all items. The filing includes 2025 executive compensation disclosures (e.g., Summary Compensation Table, equity awards, pension benefits) and director compensation details for 2021-2025 periods.

• ·Annual Meeting location: Scripps Center, 312 Walnut Street, 10th Floor Conference Center, Cincinnati, Ohio
• ·Proxy materials furnished via Notice of Internet Availability on or about March 20, 2026
• ·Compensation disclosures cover PEO and Non-PEO NEO for periods 2021-2025, including equity awards adjustments, pension service costs, and change in fair value of outstanding equity

20-03-2026

InflaRx N.V. (IFRX) filed its 20-F Annual Report on March 20, 2026, outlining key expense categories across operations. These include external services for GOHIBIC distribution and commercial infrastructure, employee-related costs such as salaries and stock-based compensation, professional fees for U.S. market access, R&D expenses with CROs and CDMOs, and legal fees for IP protection and other matters. No specific financial metrics or period-over-period comparisons are provided in the excerpt.

• ·Expenses cover CROs, CDMOs, consultants, and independent contractors for R&D, preclinical, and clinical activities.
• ·Professional fees include auditors, consultants not related to R&D, and lawyers not tied to IP.

20-03-2026

Naveen Krishna, Executive Vice President and Chief Information & Digital Officer of Genuine Parts Company (GPC), notified his voluntary resignation effective April 1, 2026, to pursue other opportunities, with no severance benefits provided. He will remain an employee until May 5, 2026, to ensure an orderly transition. The company plans to reallocate his responsibilities to other individuals without appointing a successor at this time.

• ·Event reported on March 18, 2026; filing dated March 20, 2026
• ·GPC common stock trades as GPC on NYSE

20-03-2026

Aquestive Therapeutics, Inc. (AQST) announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026, succeeding Lori J. Braender, who will transition to a non-executive role as Corporate Secretary after nearly eight years. Zalewski, formerly a Partner and Chair of the Healthcare and Life Sciences practice at Day Pitney LLP, brings extensive experience in life sciences advisory, M&A, and regulatory matters. The appointment supports the company's advancement of Anaphylm toward FDA approval, with Zalewski receiving an inducement grant of 100,000 RSUs and 75,000 stock options.

• ·Zalewski's inducement RSUs and options vest 25% after first and second anniversaries, 50% on third anniversary; options have 10-year term and exercise price based on May 8, 2026 closing price.
• ·Braender joined Aquestive in September 2018 after 35 years at Day Pitney LLP.
• ·Grants approved under 2022 Equity Inducement Plan per Nasdaq Rule 5635(c)(4) by independent Compensation Committee.

20-03-2026

PEDEVCO Corp. published an updated company presentation on its website (www.pedevco.com) on March 20, 2026, furnished as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. The filing includes standard forward-looking statements disclaimers and references to prior SEC filings like the Form 10-K for year ended December 31, 2024, and Form 10-Q for quarter ended September 30, 2025. No specific financial metrics, performance data, or period-over-period comparisons are disclosed in the filing.

• ·Company address: 575 N. Dairy Ashford, Suite 210, Houston, Texas 77079
• ·Common Stock trades on NYSE American under symbol PED

20-03-2026

Aveanna Healthcare Holdings Inc. (AVAH) furnished an investor presentation under Item 7.01 of Form 8-K on March 20, 2026, attached as Exhibit 99.1 and available on ir.aveanna.com. The filing notes that website and social media are used for material company information distribution. No specific financial metrics or performance data are disclosed in the filing itself.

• ·Securities registered: Common Stock, par value $0.01 per share (AVAH) on Nasdaq.
• ·Principal executive offices: 400 Interstate North Parkway SE, Atlanta, Georgia 30339.
• ·IRS Employer Identification No.: 81-4717209.

20-03-2026

Katapult Holdings, Inc. filed a DEFA14A Definitive Additional Materials proxy statement on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. No fee was required for the filing, and it was filed by the registrant. The document contains no quantitative financial data, performance metrics, or specific proposals at this time.

• ·Filing categorized as Definitive Additional Materials under Schedule 14A.

20-03-2026

Arrowhead Pharmaceuticals held its 2026 Annual Meeting of Stockholders on March 19, 2026, where all seven director nominees were elected despite significant opposition for some, such as Michael Perr (70.4M FOR vs. 31.3M AGAINST), Hongbo L (92.7M FOR vs. 9.0M AGAINST), and William Waddill (91.9M FOR vs. 9.9M AGAINST). The advisory Say-on-Pay proposal failed decisively with 41.6M FOR and 60.0M AGAINST, while the Amended and Restated 2021 Incentive Plan passed with 99.2M FOR and ratification of KPMG LLP as auditors passed overwhelmingly with 119.1M FOR.

• ·Record date for Annual Meeting: January 22, 2026
• ·Fiscal year for KPMG audit: ending September 30, 2026
• ·Christopher Anzalon director votes: 100,146,366 FOR; 1,622,011 AGAINST; 77,607 ABSTAIN
• ·Mauro Ferrar director votes: 99,784,848 FOR; 1,986,678 AGAINST; 74,458 ABSTAIN
• ·Hongbo L director votes: 92,692,428 FOR; 8,971,012 AGAINST; 182,544 ABSTAIN
• ·Adeoye Olukoto director votes: 100,808,855 FOR; 852,631 AGAINST; 184,498 ABSTAIN
• ·Victoria Vakiene director votes: 99,264,191 FOR; 2,506,051 AGAINST; 75,742 ABSTAIN
• ·William Waddill director votes: 91,907,466 FOR; 9,861,644 AGAINST; 256,341 ABSTAIN
• ·Say-on-Pay: 256,341 ABSTAIN
• ·Incentive Plan: 2,401,793 AGAINST; 285,915 ABSTAIN
• ·KPMG ratification: 371,668 AGAINST; 376,706 ABSTAIN

20-03-2026

The Hackett Group, Inc. (HCKT) filed its DEF 14A proxy statement for the 2026 Annual Meeting on April 30, 2026, seeking shareholder approval for electing one director nominee, amending the Employee Stock Purchase Plan to add 250,000 authorized shares and extend its term to July 1, 2031, an advisory vote on executive compensation, and ratification of RSM US LLP as auditors for the fiscal year ending January 1, 2027. The record date is March 13, 2026, with proxy materials distributed on or about March 20, 2026. No financial performance metrics or period-over-period comparisons are detailed in the filing.

• ·Annual Meeting location: 1001 Brickell Bay Drive, 30th Floor, Miami, Florida at 11:00 a.m. local time
• ·Fiscal year for auditor ratification ends January 1, 2027
• ·Shareholder list available for examination 10 days prior to meeting

20-03-2026

Orion Properties Inc. (ONL) issued its 2026 DEF 14A Proxy Statement for the virtual Annual Meeting on May 13, 2026 (record date March 13, 2026), seeking stockholder approval to elect five director nominees and ratify KPMG LLP as independent auditor for FY ending December 31, 2026. As of December 31, 2025, the portfolio includes 58 operating properties (6.5M sq ft across 26 states) and a 20% interest in a JV with six properties (1.0M sq ft), totaling 6.7M rentable sq ft at 78.7% occupancy (78.2% adjusted for properties under sale agreements). The company, a REIT spun off from Realty Income in 2021, remains an emerging growth company until December 31, 2026.

• ·Annual Meeting at 11:30 A.M. ET, virtual via www.virtualshareholdermeeting.com/ONL2026.
• ·Weighted average remaining lease term of 5.7 years as of Dec 31, 2025.
• ·Common stock par value $0.001 per share.
• ·Company will lose emerging growth company status on Dec 31, 2026.
• ·Principal office: 3200 E Camelback Road, Suite 100, Phoenix, Arizona 85018.